Edition:
United States

Rigel Pharmaceuticals Inc (RIGL.OQ)

RIGL.OQ on NASDAQ Stock Exchange Global Select Market

3.87USD
16 Feb 2018
Change (% chg)

$-0.08 (-2.03%)
Prev Close
$3.95
Open
$3.92
Day's High
$3.99
Day's Low
$3.81
Volume
159,385
Avg. Vol
440,649
52-wk High
$4.71
52-wk Low
$2.15

Chart for

About

Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s pioneering research focuses on signaling... (more)

Overall

Beta: 1.27
Market Cap(Mil.): $566.92
Shares Outstanding(Mil.): 146.49
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib

* RIGEL PHARMACEUTICALS - ‍FDA HAS CONFIRMED IT DOES NOT PLAN TO CONVENE ONCOLOGY DRUGS ADVISORY COMMITTEE MEETING TO DISCUSS NDA FOR FOSTAMATINIB​

Jan 04 2018

BRIEF-Rigel Announces Resignation Of Ryan Maynard, Executive Vice President And CFO Effective December 31, 2017

* RESIGNATION OF RYAN MAYNARD, EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, EFFECTIVE DECEMBER 31, 2017

Dec 15 2017

BRIEF-Rigel announces Q3 loss of $0.14 per share

* Rigel announces third quarter 2017 financial results and provides company update

Nov 07 2017

BRIEF-Rigel announces pricing of public offering of common stock

* Says public offering of 18.1 million common shares priced at $3.35 per share Source text for Eikon: Further company coverage:

Oct 04 2017

BRIEF-Rigel announces proposed public offering of common stock

* Rigel Pharmaceuticals Inc - intends to offer and sell up to $40 million of shares of its common stock in an underwritten public offering

Oct 03 2017

BRIEF-RIGEL PHARMACEUTICALS SAYS FOSTAMATINIB MEETS PRE-SPECIFIED GOAL IN STAGE 1 OF AIHA PHASE 2 STUDY

* FOSTAMATINIB MEETS PRE-SPECIFIED PRIMARY ENDPOINT IN STAGE 1 OF AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA) PHASE 2 STUDY

Oct 03 2017

BRIEF-Rigel provides update on FDA review of fostamatinib for ITP

* Rigel provides update on FDA review of fostamatinib for ITP

Oct 02 2017

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF79.68 --
Roche Holding Ltd. (ROG.S) CHF223.15 --
Roche Holding Ltd. (RO.S) CHF226.00 --
Merck & Co., Inc. (MRK.N) $56.29 +0.30
Sanofi SA (SASY.PA) €64.30 --
AstraZeneca plc (AZN.L) 4,712.50 -27.00
Abbott Laboratories (ABT.N) $60.17 +0.67

Earnings vs. Estimates